Co-Diagnostics Price to Free Cash Flow Ratio 2017-2024 | CODX

Co-Diagnostics price to free cash flow ratio from 2017 to 2024. Price to free cash flow ratio can be defined as

Co-Diagnostics Price to Free Cash Flow Ratio 2017-2024 | CODX

Co-Diagnostics price to free cash flow ratio from 2017 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Elevance Health (ELV)$125.1B
Cencora (COR)$45B
ICON (ICLR)$25B
DiDi Global (DIDIY)$19B
Avantor (AVTR)$18.4B
Natera (NTRA)$15.7B
Revvity (RVTY)$15.4B
Viatris (VTRS)$14.2B
CochLear (CHEOY)$12.8B
Solventum (SOLV)$12.5B
Medpace Holdings (MEDP)$11.2B
Charles River Laboratories (CRL)$10.6B
Sonic Healthcare (SKHHY)$8.8B
Doximity (DOCS)$7.4B
Bausch + Lomb (BLCO)$7B
HealthEquity (HQY)$6.8B
PACS (PACS)$6.2B
Organon (OGN)$5.1B
Life Times (LTH)$4.9B
Sotera Health (SHC)$4.7B
Surgery Partners (SGRY)$4.1B
Concentras Parent (CON)$3B
GoodRx Holdings (GDRX)$2.8B
BrightSpring Health Services (BTSG)$2.5B
Ardent Health Partners (ARDT)$2.4B
Progyny (PGNY)$2.2B
Alignment Healthcare (ALHC)$2.2B
Premier (PINC)$2.1B
Ryman Healthcare (RYHTY)$1.9B
AMN Healthcare Services Inc (AMN)$1.8B